Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
US Department of Justice
Citi
Argus Health
Cipla
Cantor Fitzgerald
Dow
Colorcon
Deloitte

Generated: October 22, 2018

DrugPatentWatch Database Preview

Tygacil Drug Profile

« Back to Dashboard

When do Tygacil patents expire, and when can generic versions of Tygacil launch?

Tygacil is a drug marketed by Pf Prism Cv and is included in one NDA. There are five patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in TYGACIL is tigecycline. There are ten drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the tigecycline profile page.

Drug patent expirations by year for Tygacil
Pharmacology for Tygacil
Synonyms for Tygacil
(4S,12aS)-4,7-Bis(dimethylamino)-9-{2-[(tert-butyl)amino]acetylamino}-3,10,12,12a-tetrahydroxy-1,11-dioxo-4,5,6,12a,4a,5a-hexahydronaphthacene-2-carboxamide
(4S,4aS,5aR,12aS)-9-(2-(tert-butylamino)acetamido)-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide
(4S,4aS,5aR,12aS)-9-(2-(tert-Butylamino)acetamido)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1
(4S,4AS,5aR,12aS)-9-(2-(tert-butylamino)acetamido)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxa
(4S,4aS,5aR,12aS)-9-(2-(tert-butylamino)acetamido)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
(4S,4aS,5aR,12aS)-9-[(N-tert-butylglycyl)amino]-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
(4S,4aS,5aR,12aS)-9-[[2-(tert-butylamino)acetyl]amino]-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide
(4S,4aS,5aR,12aS)-9-[2-(tert-butylamino)acetamido]-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
121GE002
2-Naphthacenecarboxamide, 4,7-bis(dimethylamino)-9-((((1,1-dimethylethyl)amino)acetyl)amino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)-
2-Naphthacenecarboxamide, 4,7-bis(dimethylamino)-9-((((1,1-dimethylethyl)amino)acetyl)amino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)-
2-NAPHTHACENECARBOXAMIDE, 4,7-BIS(DIMETHYLAMINO)-9-[[[(1,1-DIMETHYLETHYL)AMINO]ACETYL]AMINO]-1,4,4A,5,5A,6,11,12A-OCTAHYDRO-3,10,12,12A-TETRAHYDROXY-1,11-DIOXO-, (4S,4AS,5AR,12AS)-
2-Naphthacenecarboxamide, 4,7-bis(dimethylamino)-9-[[2-[(1,1-dimethylethyl)amino]acetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)-
220620-09-7
220620-09-7 (anhy.)
620T097
70JE2N95KR
9-t-Butylglycylamido minocycline
9-t-Butylglycylamido-minocycline hydrate
9-tert-Butylglycylamidominocycline
A5226
AB0011463
AB01566818_01
AB2000089
AC-1798
AC1NQZEU
AC1O714W
ACT08710
AK-73038
AKOS015895663
AKOS025401452
AM20090708
AN-6306
BC677670
BCPP000045
BR-73038
C12012
C29H39N5O8
CAS-220620-09-7
CHEBI:149836
CHEMBL376140
CS-1876
CT0198
D01079
D0G4OD
DB00560
DSSTox_CID_28507
DSSTox_GSID_48581
DSSTox_RID_82779
DTXSID2048581
FPZLLRFZJZRHSY-HJYUBDRYSA-N
FT-0657279
GAR 936
GAR-936
GAR-936,Tigecycline
Glycylcycline
HY-B0117
I06-1089
LS-186580
LS-187002
LS-187782
MFCD00935753
MLS006010079
MolPort-009-199-379
MolPort-028-751-260
N-((5aR,6aS,7S,10aS,Z)-9-(amino(hydroxy)methylene)-4,7-bis(dimethylamino)-1,10a,12-trihydroxy-8,10,11-trioxo-5,5a,6,6a,7,8,9,10,10a,11-decahydrotetracen-2-yl)-2-(tert-butylamino)acetamide
N-[(5aR,6aS,7S,9E,10aS)-9-[amino(hydroxy)methylidene]-4,7-bis(dimethylamino)-1,10a,12-trihydroxy-8,10,11-trioxo-5a,6,6a,7-tetrahydro-5H-tetracen-2-yl]-2-(tert-butylamino)acetamide
N-[(5aR,6aS,7S,9Z,10aS)-9-[amino(hydroxy)methylene]-4,7-bis(dimethylamino)-1,10a,12-trihydroxy-8,10,11-trioxo-5a,6,6a,7-tetrahydro-5H-tetracen-2-yl]-2-(tert-butylamino)acetamide
N-[(5AR,6AS,7S,9Z,10AS)-9-[AMINO(HYDROXY)METHYLIDENE]-4,7-BIS(DIMETHYLAMINO)-1,10A,12-TRIHYDROXY-8,10,11-TRIOXO-5,5A,6,6A,7,8,9,10,10A,11-DECAHYDROTETRACEN-2-YL]-2-(TERT-BUTYLAMINO)ACETAMIDE
N-[(5aR,6aS,7S,9Z,10aS)-9-[amino(hydroxy)methylidene]-4,7-bis(dimethylamino)-1,10a,12-trihydroxy-8,10,11-trioxo-5a,6,6a,7-tetrahydro-5H-tetracen-2-yl]-2-(tert-butylamino)acetamide
NCGC00183095-01
PL010867
PL050681
PubChem21336
Q-101396
RL02680
S-5066
s1403
SC-20200
SCHEMBL101795
SCHEMBL105082
SCHEMBL237962
SMR002530064
SOVUOXKZCCAWOJ-HJYUBDRYSA-N
ST2413997
SYN3024
TBG-MINO
Tigeciclina
Tigecyclin
Tigecycline
Tigecycline (JAN/USAN)
Tigecycline [USAN:INN:BAN]
Tigecycline [USAN]
Tigecycline hydrate
Tigecycline, Antibiotic for Culture Media Use Only
Tigecyclinum
Tigilcycline
Tox21_112910
Tygacil (TN)
Tygacil, GAR-936, WAY-GAR-936, TBG-MINO, Tigecycline
Tygacil;GAR-936;WAY-GAR-936;TBG-MINO
Tygacil(TM)
UNII-70JE2N95KR
WAY-GAR-936
ZINC100022633
ZINC102200515
ZINC14879972

US Patents and Regulatory Information for Tygacil

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pf Prism Cv TYGACIL tigecycline POWDER;INTRAVENOUS 021821-001 Jun 15, 2005 AP RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Pf Prism Cv TYGACIL tigecycline POWDER;INTRAVENOUS 021821-001 Jun 15, 2005 AP RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Pf Prism Cv TYGACIL tigecycline POWDER;INTRAVENOUS 021821-001 Jun 15, 2005 AP RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Pf Prism Cv TYGACIL tigecycline POWDER;INTRAVENOUS 021821-001 Jun 15, 2005 AP RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for Tygacil

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pf Prism Cv TYGACIL tigecycline POWDER;INTRAVENOUS 021821-001 Jun 15, 2005 ➤ Try a Free Trial ➤ Try a Free Trial
Pf Prism Cv TYGACIL tigecycline POWDER;INTRAVENOUS 021821-001 Jun 15, 2005 ➤ Try a Free Trial ➤ Try a Free Trial
Pf Prism Cv TYGACIL tigecycline POWDER;INTRAVENOUS 021821-001 Jun 15, 2005 ➤ Try a Free Trial ➤ Try a Free Trial
Pf Prism Cv TYGACIL tigecycline POWDER;INTRAVENOUS 021821-001 Jun 15, 2005 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for TYGACIL
Drugname Dosage Strength RLD Date
➤ Subscribe For Injection 50 mg per vial ➤ Subscribe ➤ Try a Free Trial

Supplementary Protection Certificates for Tygacil

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
06/030 Ireland ➤ Try a Free Trial PRODUCT NAME: TIGECYCLINE OR A PHARMACOLOGICALLY ACCEPTABLE ORGANIC OR INORGANIC SALT OR METAL COMPLEX THEREOF; REGISTRATION NO/DATE: EU/1/06/336/001 20060424
C0031 France ➤ Try a Free Trial PRODUCT NAME: TIGECYCLINE; REGISTRATION NO/DATE: EU/01/06/336/001 20060424
C/GB06/033 United Kingdom ➤ Try a Free Trial PRODUCT NAME: TIGECYCLINE
0244 Netherlands ➤ Try a Free Trial PRODUCT: TIGECYCLINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF METAALCOMPLEX, IN HET BIJZONDER TIGECYCLINE; FIRST REGISTRATION, DATE: EU/1/06/336/001, 20060424
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
US Department of Justice
Citi
Argus Health
Cipla
Cantor Fitzgerald
Dow
Colorcon
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.